RNA Based Therapeutics Market Size, Share, Trends, Growth 2032

RNA Based Therapeutics Market: Overview

The global rna based therapeutics market size was worth around USD 13.66 billion in 2023 and is predicted to grow to around USD 24.07 billion by 2032 with a compound annual growth rate (CAGR) of roughly 6.50% between 2024 and 2032.

Request Free Sample

The report covers a forecast and an analysis of the RNA based therapeutics market on a global and regional level. The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion). The study includes drivers and restraints of the RNA based therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the RNA based therapeutics market on a global and regional level.

RNA Based Therapeutics Market: Growth Drivers

Technological advances witnessed in biopharmaceutical drugs have widened the scope of RNA-based therapeutics for treating various human diseases. RNA-based therapeutics is gaining importance for various disease targets, such as HIV, genetic disorders, different types of cancers, etc. RNA-based therapeutics includes therapeutic ribozymes, small interfering RNAs (siRNAs), and aptamers along with demonstrating extraordinary usefulness of RNA.

Worldwide cancer prevalence is increasing rapidly. In 2018, cancer was the second leading death cause globally. There were nearly 18.1 million new cancer cases and 9.6 million deaths across the globe in the same year. With increasing cancer cases, there is a growing demand for selective target specific treatment options, such as RNA-based therapeutics. The rising preference for targeted therapy due to its fewer side effects over traditional therapy is driving the RNA based therapeutics market globally. Additionally, strategic partnerships and funding for research and development, increasing public-private investments, and growing government support and funding for research and development are likely to further boost the market growth.

Request Free Sample

Other factors contributing to the RNA based therapeutics market growth are technological advancements, such as RNAi interference technology, SMaRT technology and antisense technology, increasing geriatric population base, rising chronic disease burden, and growing healthcare spending. However, high research and development cost of RNA-based therapeutics may limit the global RNA based therapeutics market growth. Alternatively, emerging markets and early commercialization of pipeline therapeutics to gain a competitive advantage may bring opportunities for the RNA-based therapeutics manufacturers.

In order to give the users of this report a comprehensive view of the RNA based therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the RNA based therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the RNA based therapeutics market on a global and regional basis.

RNA Based Therapeutics Market : Report Scope

RNA Based Therapeutics Market: Segmentation

The study provides a decisive view of the RNA based therapeutics market by segmenting it based on technology, application, end-user, and region.

Based on technology, the market includes enabling technologies and enabled technologies. Enabling technology segment is sub-categorized into labeling, microarrays, linear amplification, purification, inhibition, and qRT-PCR. The enabled technology segment is sub-categorized into RNA Interference (RNAi) technologies (microRNA and small interfering RNA) and RNA antisense technologies. Based on application, the market includes kidney diseases, cardiovascular, metabolic disorders, infectious diseases, oncology, and others. The oncology segment held the largest share of the global RNA based therapeutics market in 2018. Therapeutics, research, diagnostics, and others comprise the end-user segment of the RNA based therapeutics market. The research segment dominated the global RNA based therapeutics market in 2018.

RNA Based Therapeutics Market: Regional Analysis

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., Germany, France, UK, China, Japan, India, and Brazil.

North America dominated the global RNA based therapeutics market in 2018 with a revenue share of about 40%. The presence of key market players, increasing investments in RNA-based therapeutics research, favorable government funding policies, availability of developed research infrastructure, advancements made in RNA platform technologies are driving the North American RNA based therapeutics market growth. The Asia Pacific RNA based therapeutics market is expected to offer several growth opportunities to the major players.

RNA Based Therapeutics Market: Competitive Analysis

The global RNA based therapeutics market is led by players like:

• Quark Pharmaceuticals
• Alnylam Pharmaceuticals
• Dicerna Pharmaceuticals
• Tekmira Pharmaceuticals
• Benitec Biopharma
• Genzyme Corporation
• Ionis Pharmaceuticals
• Silence Therapeutics
• Cenix BioScience
• Sirnaomics

This report segments the global RNA based therapeutics market into:

Global RNA Based Therapeutics Market: By Technology

• Enabling Technology
  • Microarrays
  • Labeling
  • Purification
  • Linear Amplification
  • qRT-PCR
  • Inhibition
• Enabled Technology
  • RNA Interference (RNAi) Technologies
    • Small Interfering RNA (siRNA)
    • MicroRNA (miRNA)
  • RNA Antisense Technologies

Global RNA Based Therapeutics Market: By Application

• Cardiovascular
• Kidney Diseases
• Oncology
• Infectious Diseases
• Metabolic Disorders
• Others

Global RNA Based Therapeutics Market: By End-User

• Research
• Therapeutics
• Diagnosis
• Others

Global RNA Based Therapeutics Market: By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa